Digest Network Come funziona
Network
/
Società
Ba
Non verificato

Bayer

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

173 comunicati stampa

Guarda tutti i comunicati
17/09/2026
Robigo and Leaps by Bayer Announce Series A Financing to Advance Engineered Biologicals That Protect Yields and Reduce Costs
Fonte
Bayer
Emittente
Business Wire
1.00
0
17/09/2026
Biotecnologia
Igiene alimentare
Sanità
Salute
Farmaceutica
Scienza
Medicina - Varie
Industria
Bayer’s KERENDIA® (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 Diabetes
Fonte
Bayer
Emittente
Business Wire
1.00
0
10/09/2026
Bayer Launches Nationwide Science Delivers Tour to Take Science on the Road
Fonte
Bayer
Emittente
Business Wire
1.00
0
10/09/2026
Industria
Oncologia
Salute
Igiene alimentare
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
U.S. FDA Grants Accelerated Approval to Bayer’s HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung Cancer
Fonte
Bayer
Emittente
Business Wire
1.00
0
09/09/2026
Mercato del lavoro
Industria
Energie Rinnovabili
Energia
Agricoltura
Materie prime
Bayer and Neste Close Commercial Agreement to Jointly Scale newgold® Winter Canola for Biofuels Production
Fonte
Bayer
Emittente
Business Wire
1.00
0
09/09/2026
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Cardiologia
Biotecnologia
BAYER INITIATES PHASE II STUDY OF INVESTIGATIONAL GIRK4 INHIBITOR IN PATIENTS WITH ATRIAL FIBRILLATION
Fonte
Bayer
Emittente
Business Wire
1.00
0
02/09/2026
Industria
Tecnica
Agricoltura
Materie prime
Scienza
Bayer Advances Combined Seed and Crop Protection Pipeline and Enters Phase of Blockbuster Launches
Fonte
Bayer
Emittente
Business Wire
1.00
0
30/08/2026
Eventi
Industria
Scienza
Cardiologia
Medicina nucleare
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Bayer Announces Phase III REVEAL Study with Investigational PET Radiotracer Iodine 124 Evuzamitide Presented as Late-Breaker at ESC 2026
Fonte
Bayer
Emittente
Business Wire
1.00
0
20/08/2026
Eventi
Industria
Scienza
Cardiologia
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Bayer to Present New Phase III Data from Its Cardiovascular, Kidney, and Stroke Clinical Trial Programs at ESC 2026
Fonte
Bayer
Emittente
Business Wire
1.00
0
28/07/2026
Multimedialità
Industria
Pubblico Esercizio/Vendita al dettaglio
Fitness
Sanità
Salute
Vetrine/Shopping
Farmaceutica
One A Day® Introduces New Women's Multi Gummy Formula with 1,000 mcg Biotin
Fonte
Bayer
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0